Physician profile
Leonel Apodaca
NPI 1699883157
$1,765.99
in general payments reported to CMS, 2019-2025
13 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $231 · 2021: $487 · 2022: $284 · 2023: $225 · 2024: $146 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $916.32 | 2020-2025 | Jardiance, Ofev, Spiriva Respimat |
| Novo Nordisk INC | $232.35 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $171.55 | 2022-2025 | Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $155.28 | 2020-2021 | |
| Mylan Specialty L.P. | $73.83 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $66.86 | 2021 | |
| Lilly USA, LLC | $35.11 | 2021-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.88 | 2021-2023 | Xifaxan |
| Horizon Therapeutics Plc | $19.50 | 2021 | |
| Dermira, INC. | $19.42 | 2020 | |
| Abbott Laboratories | $17.52 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.08 | 2024 | |
| Hologic Sales and Service, LLC | $14.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonel Apodaca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.